
    
      A Phase 2b randomised, double-blind, placebo-controlled and open-label active comparator
      study to evaluate the effect of Cotadutide at 100, 300 or 600 micrograms in participants who
      have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

      The study plans to randomise approximately 225 subjects. Subjects will be randomised to
      receive double-blind Cotadutide or placebo at 100, 300 or 600 micrograms once daily for 26
      weeks, or open-label semaglutide at 1.0 miligrams once a week for 26 weeks. Japanese
      participants will not be randomised to the semaglutide arm.
    
  